inversores

FIRST U.S. PATIENT TREATED IN SINGLE-LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, March 2nd, 2021 – Spineart USA Inc. announced today that investigator, Dr. Byron Branch, at Carolina Neurosurgery and Spine Associates in Charlotte NC, performed the first surgery in the single-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following single-level discectomy for symptomatic cervical disc disease. Descargar las noticias de prensa Descargar las noticias de prensa

FIRST U.S. PATIENT TREATED IN TWO-LEVEL IDE CLINICAL TRIAL OF BAGUERA® C CERVICAL DISC PROSTHESIS

LAGUNA HILLS, CA, February 26, 2021 – Spineart USA Inc. announced today that clinical principal investigator, Dr. Domagoj Coric at Carolina Neurosurgery and Spine Associates and Spine Division Chief at Atrium Musculoskeletal Institute in Charlotte NC, performed the first surgery in the two-level U.S. Investigational Device Exemption (IDE) Clinical Trial of the BAGUERA® C Cervical Disc Prosthesis. The BAGUERA® C implant is an investigational device designed to reconstruct the cervical disc following two-level discectomy at adjacent segments for symptomatic cervical disc disease. Descargar las noticias de prensa Descargar las noticias de prensa

Spineart reaches definitive agreement to acquire Meditech Spine LLC.

Spineart, a global spine player with headquarters in Geneva, Switzerland and US operations in Laguna Hills, California, has agreed to acquire 100% of Atlanta-based Meditech Spine LLC.Spineart has been a distributor of Meditech Spine’s products in the US since 2019. The companies anticipate significant synergies between the two organizations. As part of the transaction, Meditech Spine’s co-founder and chief executive officer, Eric Flickinger, will join Spineart’s senior management team in the US. Meditech manufactures and markets a portfolio of sterile-packed, barcoded CURE® plates and TALOS® PEEK-HA cages in the US. Spineart manufactures and markets a comprehensive portfolio of sterile-packed, barcoded spinal posterior fixations, 3D-printed Ti-LIFE cages, artificial disc prosthesis and biologics in 50 countries. The transaction is expected to close in July 2020. Descargar las noticias de prensa Descargar las noticias de prensa

Spineart secured CHF 50 million investment from EGS Beteiligungen AG, a swiss growth equity fund.

Spineart today announces that it secured a CHF 50 million investment from EGS Beteiligungen AG, which thus becomes a cornerstone investor in the company next to the Management and Gimv, its largest shareholder. These proceeds will be used to implement strategic clinical studies, accelerate Spineart’s organic growth in key markets, seize selective acquisition opportunities and for continued development and launch of superior technologies. Descargar las noticias de prensa Descargar las noticias de prensa

Spineart announces acquisition of Eden Spine Europe’s assets

Spineart SA is pleased to announce that it has recently acquired assets from Eden Spine Europe SA, a Geneva based company specializing in spinal implants.This acquisition complements Spineart’s existing portfolio in particular with a cervico-thoracolumbar VBR system and an Antero-Lateral Plate.

Spineart announces Executive Appointment

Alex Moussa joins Spineart as Chief Operating Officer.Spineart is pleased to announce the arrival of Dr. Alex Moussa as Chief Operating Officer, effective November 11th, 2019.Alex is a senior Executive Leader in the Medical devices industry, with a PhD in Pharmaceutical Sciences and a track record of success in building new business ventures, accelerating growth and in re-invigorating mature businesses. Alex spent the last 17 years at Medtronic where he led regional business units in diabetes, spine, biopharma and cardiology before serving as Vice President and President of Kanghui Orthopedics in China and VP of Cardiac Rhythm & Heart Failure in EMEA.«Attracting a professional of the calibre and experience of Alex to the key role of COO is a testament to the commitment of Spineart to sustained growth and success. We are delighted to welcome him to Spineart.» said Stéphane Mugnier-Jacob, Co-CEO & Co-Founder of Spineart.Alex added «I’m thrilled to join such a dynamic and talented team that has made this company one of the most innovative challengers in the spine industry.»About Spineart